The best DNA test for your health depends on what you actually want to learn. For general disease-risk context with the strongest regulatory backing in the consumer market, 23andMe is the starting point. For clinical-grade hereditary cancer or carrier screening your doctor can act on, Color and Invitae are the picks. For pharmacogenomics (how your body processes medications), ClarityX is the focused option. For biological age, TruDiagnostic. For the deepest raw data, Sequencing.com’s whole genome kit.
We grouped this roundup by use case rather than by brand because the same word (“health”) covers four different products with four different evidence bars. Most roundups don’t make that distinction, which is why people end up buying a wellness kit when they wanted a carrier panel.
What “best for health” actually means
Consumer genetic testing sells under one banner but reports four very different things. Matching the test to the question matters more than the price or the brand.
The four use cases:
- Disease-risk screening. Probabilistic information about common conditions like Type 2 diabetes, late-onset Alzheimer’s, or hereditary thrombophilia. Mostly statistical-association results, occasionally backed by specific FDA-authorized reports.
- Carrier screening. Whether you carry a recessive variant for conditions like cystic fibrosis or sickle cell disease that you could pass to a child. Useful for family planning. ACMG recommends expanded carrier screening for any pregnancy or preconception conversation.
- Pharmacogenomics (PGx). How your genes affect drug metabolism, relevant for psychiatric medications, blood thinners, pain medication, and several cancer drugs.
- Biological age and wellness. Epigenetic measurements that estimate how quickly your body is aging, or lifestyle reports that translate genetics into nutrition and fitness guidance. These are not inherited-risk tests.
The three risk classes (and why they matter)
Every health DNA claim falls into one of three categories. Mixing them up is the single most common source of confusion when people read a DNA report.
- Monogenic. A change in one gene is the main driver of risk or disease, but how much risk, and how likely you are to develop the condition, varies by gene and inheritance pattern. A pathogenic BRCA1 or BRCA2 variant raises the chance of hereditary breast and ovarian cancer significantly, but having one doesn’t guarantee cancer: the National Cancer Institute’s BRCA fact sheet notes a positive result cannot tell whether or when someone will develop cancer. Cystic fibrosis is recessive: it usually requires changes in both copies of the CFTR gene, so a single CFTR variant typically means carrier status, not the disease. Huntington’s is the cleanest high-penetrance example, with some reduced-penetrance repeat ranges at the boundary. Clinical-grade panels from Color and Invitae specialize in this tier. 23andMe’s BRCA report is a partial monogenic readout against a narrow variant list.
- Polygenic. Many variants each contribute a small effect, and the combined number is called a polygenic risk score (PRS). PRS estimates likelihood of developing a common disease relative to the population average. The National Human Genome Research Institute notes PRS expresses relative risk rather than baseline or timeframe, and shows correlation rather than causation.
- Statistical association. Small-effect variants tied to a trait at the population level. Most DTC “health” reports (including the bulk of what 23andMe, TellMeGen, SelfDecode, and LifeDNA show) fall in this class. Useful as context, not for medical decisions.
Most direct-to-consumer kits report the third class, with selected exceptions in the first (BRCA, carrier status) and second (PRS-style risk for common diseases). Clinical-grade panels report the first. A “PRS for breast cancer” is not the same finding as a “BRCA1 pathogenic variant,” even though both can appear under a “breast cancer risk” headline.
A short disclaimer worth taking seriously
DTC genetic health reports don’t diagnose disease. A flagged variant is a starting point for a conversation with a healthcare provider, not a treatment change. The FDA’s special controls for genetic health risk reports state these tests do not determine overall disease risk and are not intended to diagnose disease or make medical decisions. Clinical genetic tests (the kind your doctor orders through a lab like Color or Invitae) are a different category: in the right clinical context, they can sometimes establish or confirm a hereditary diagnosis or predisposition. Even then, results still need medical interpretation before any screening, prevention, or treatment decision follows. Use DTC kits as screening and education; let clinical-grade tests do the diagnostic work.
DNA health tests that are no longer available: what to do instead
Several services that show up in older roundups have been discontinued or restructured. Knowing what happened to each is part of picking the right active replacement.
- AncestryDNA Health (AncestryHealth Core, AncestryHealth Plus): discontinued 2021. Ancestry sunset its DTC health products in early 2021 and now sells only the ancestry-only kit. For the DTC health use case, 23andMe is the canonical successor. For clinical-grade carrier or cancer screening (what AncestryHealth Plus tried to be), Color or Invitae fit better.
- Sema4 (consumer-genetic-testing arm): restructured 2022. Sema4 merged into the GeneDx AI/data business in 2022; the consumer-clinical-genetic-testing assets were restructured. Sema4 is no longer a viable consumer recommendation. Invitae (now under Labcorp) is the closest active analog for carrier and hereditary cancer testing.
- MyHeritage Health: discontinued. MyHeritage retired its health add-on; the platform now sells ancestry only.
What about at-home health labs?
At-home health labs aren’t DNA tests, but they show up in the same SERP because the buying intent overlaps. Worth naming so the taxonomy stays honest.
- InsideTracker. Blood biomarker testing (cholesterol, glucose, hormones, inflammation markers) with an optional DNA add-on. As of May 2026, kits start at $189 (Essentials) and reach $589 (Ultimate). A natural complement to a DNA kit when you want both inherited-risk context and current-state biomarker data; not a substitute for a DNA test.
- Everlywell. Individual at-home lab tests for food sensitivity, hormones, thyroid, STI panels, and others. Pricing ranges roughly $49 to $259 per test as of May 2026. Useful for targeted lab follow-ups, unrelated to inherited-risk testing.
Neither is a DNA test; treat them as adjacent rather than competitive.
What health DNA tests can and cannot tell you
The limits look different for each risk class. Treating “DTC kit” and “clinical-grade panel” as the same kind of test is where most misunderstandings start.
What DTC statistical-association tests can do
- Flag broad risk patterns for common conditions like Type 2 diabetes, certain cancers, or cardiovascular conditions. The signal is probabilistic and population-level.
- Surface useful carrier status for the conditions a kit’s selected-variant panel covers, with the caveat that a negative result only rules out the variants on that panel, not all carrier variants.
- Provide pharmacogenetic context for a handful of variant–drug pairs.
- Estimate biological age (epigenetic tests like TruDiagnostic) or quantify lifestyle effects on aging trajectory.
- Establish a baseline raw dataset you can revisit as research grows.
What DTC tests cannot do
- They cannot diagnose a disease. A flagged variant prompts a conversation with a healthcare provider.
- They cannot cover the full variant landscape for a given condition. 23andMe’s BRCA report includes 44 variants; the FDA notes that’s out of more than 4,000 known BRCA1/BRCA2 variants linked to cancer risk. The same logic applies to most selected-variant panels.
- They cannot replace clinical-grade testing for a confirmed medical question. A negative DTC result is not a negative clinical result.
- They cannot escape false positives. Peer-reviewed work in Genetics in Medicine documented false-positive results from DTC raw-data and third-party interpretation, especially for clinically relevant variants sent for confirmation. Clinical-lab confirmation is the appropriate next step before any decision changes.
What clinical-grade monogenic tests can do that DTC kits cannot
- Analyze the relevant genes more comprehensively than selected-variant DTC kits, and interpret pathogenic or likely pathogenic variants under ACMG/AMP-aligned criteria, with stated assay limitations.
- Provide a clinically actionable result a physician can build a screening or surveillance plan around.
- Run inside an evidence chain (CLIA + CAP lab, ACMG-aligned variant interpretation, genetic counselor handoff) designed for medical decision-making.
If a clinical decision rests on the answer, the clinical-grade pathway is the correct one.
When to talk to a genetic counselor
A genetic counselor is the right next step when a result could affect a medical decision, during pregnancy planning, with a serious family-history pattern, or whenever a DTC result raises more questions than it answers. The CDC’s genetic counseling guidance treats counseling as the appropriate gate between a screening result and clinical follow-up. Most clinical-grade labs (Color, Invitae) include counseling with the panel; for a DTC result, finding a counselor through the National Society of Genetic Counselors directory is the standard path. The counselor translates a probabilistic or selected-variant result into clinical context: what to confirm, what to ignore, what to share with family, and whether confirmatory testing is appropriate.
Privacy and your DNA data
Genetic data is sensitive in ways credit-card data is not. The bankruptcy and acquisition cycle in this category over the past two years has made privacy review a non-optional step.
- 23andMe under TTAM ownership. Following the March 2025 Chapter 11 filing, TTAM Research Institute closed the asset purchase in July 2025. The privacy policy was re-issued under TTAM. Review the current policy and confirm your deletion and data-sharing preferences. Existing accounts carried over to the new ownership; pay attention to data retention, third-party research opt-in or opt-out controls, and law-enforcement access policies.
- Clinical-grade labs (Color, Invitae/Labcorp). Operate under HIPAA as covered entities, which is a meaningfully different privacy regime than the DTC framework most consumer kits use. Deletion and data-sharing rights are governed by HIPAA and lab-specific policies.
- DTC labs (Sequencing.com, SelfDecode, TellMeGen, TruDiagnostic, LifeDNA). Operate outside HIPAA for the DTC product line. Confirm the posted privacy policy with an access date, check for explicit “data is not sold” language, and confirm deletion rights and law-enforcement-access framing before submitting a sample. Upload scenarios involve a second company processing your genetic information. Review that company’s policy too.
- Insurance and employment protections. The Genetic Information Nondiscrimination Act (GINA) covers health insurance and employment, but does not cover life, disability, or long-term-care insurance. That distinction matters when deciding whether to test.
Our most private DNA tests guide covers the per-company privacy comparison in more depth.
How we evaluated these tests
We weight regulatory precision, evidence chain, and use-case fit ahead of feature counts.
- Precise FDA terminology. PMA approval, De Novo authorization, 510(k) clearance, and no FDA action carry different evidentiary bars. We use the exact filing terms (DEN160026, K223597, K193492, DEN140044) rather than a generic “FDA cleared.”
- Risk-class separation. Monogenic, polygenic, and statistical-association results report different things; we don’t blur them.
- Evidence chain per pick. Per Know Your DNA’s Hard Rule, every pick is backed either by a sibling KYD review (documented editorial evaluation) or by Tier 3 third-party reporting. For Color, Invitae, and the at-home lab adjacencies, we lean on Tier 3 third-party validation pending direct walk-throughs.
- Privacy review. Each company’s posted privacy policy is reviewed with an access date; marketing copy alone never validates a privacy claim.
- Pricing currency. Prices are access-date stamped to May 2026 because pricing in this segment changes monthly.
We did not include affiliate-marketing roundups, brand-sponsored reviews, or repackaged press releases.
The bottom line
Match the test to the question.
- DTC disease-risk plus PGx plus selected carrier reports → 23andMe, the only consumer kit with FDA-authorized and FDA-cleared reports.
- Hereditary cancer with a clinical evidence chain → Color Health.
- Carrier screening with insurance coverage potential → Invitae (now under Labcorp).
- Focused pharmacogenomic reporting → ClarityX DNA.
- Deepest raw data to revisit over time → Sequencing.com.
- Interpretation over an existing genotyping file → SelfDecode.
- International DTC availability → TellMeGen.
- Biological age and lifestyle tracking → TruDiagnostic.
- Wellness and lifestyle reports → LifeDNA.
- Biomarker context alongside DNA → InsideTracker (not a DNA test).
If you want one direct next step:
- FDA-reviewed DTC screening: Check 23andMe Price
- Clinical-grade cancer or carrier screening: Talk to your physician about Color Health or Invitae
- Pharmacogenomics: Read our ClarityX DNA review
- Broader DNA test comparison: Which DNA Test Is the Most Accurate?
- Privacy tradeoffs: Which DNA Test Is the Most Private?
- Cost guidance: The Cost of Genetic Testing
